SGX-523 is an inhibitor of MET that exhibits anticancer chemotherapeutic activity. SGX-523 inhibits growth of cells and tumors in models of non-small cell lung cancer (NSCLC). SGX-523 also improves the efficacy of co-administered treatments, further suppressing growth in animal models of lung cancer, breast cancer, and pancreatic cancer.
| Cas No. | 1022150-57-7 |
|---|---|
| Purity | ≥98% |
| Formula | C18H13N7S |
| Formula Wt. | 359.41 |
| IUPAC Name | 6-[[6-(1-methylpyrazol-4-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]sulfanyl]quinoline |
| Synonym | SGX523 |
| Appearance | Brown solid |
| Store Temp | -20°C |
|---|---|
| Ship Temp | Ambient |
| Info Sheet | S2792 Info Sheet PDF |
|---|
Zhang YW, Staal B, Essenburg C, et al. Strengthening context-dependent anticancer effects on non-small cell lung carcinoma by inhibition of both MET and EGFR. Mol Cancer Ther. 2013 Aug;12(8):1429-41. PMID: 23720767.
Zhang YW, Staal B, Essenburg C, et al. MET kinase inhibitor SGX523 synergizes with epidermal growth factor receptor inhibitor erlotinib in a hepatocyte growth factor-dependent fashion to suppress carcinoma growth. Cancer Res. 2010 Sep 1;70(17):6880-90. Erratum in: Cancer Res. 2011 Apr 1;71(7):2804. PMID: 20643778.
Buchanan SG, Hendle J, Lee PS, et al. SGX523 is an exquisitely selective, ATP-competitive inhibitor of the MET receptor tyrosine kinase with antitumor activity in vivo. Mol Cancer Ther. 2009 Dec;8(12):3181-90. PMID: 19934279.
